Investment Thesis
Rapid Micro Biosystems exhibits strong revenue growth at 19.7% YoY, but fundamentals deteriorate significantly with operating losses of -$47.4M on $33.6M revenue and negative free cash flow of -$31.9M, indicating unsustainable cash burn. While the company maintains adequate liquidity and moderate leverage, there is no clear path to profitability and the burn rate suggests limited runway without significant capital raises or dramatic margin improvement.
Strengths
- Revenue growth of 19.7% YoY demonstrates market acceptance and sales traction
- Strong liquidity position with current ratio of 3.31x and quick ratio of 2.36x provides near-term solvency
- Moderate debt-to-equity ratio of 0.57x maintains financial flexibility with $20.0M cash on hand
Risks
- Severe operating losses of -$47.4M on $33.6M revenue with -141% operating margin indicates fundamental business model challenges
- Negative free cash flow of -$31.9M represents unsustainable cash burn rate that will deplete $20M cash reserves within 8 months
- Operating income deterioration despite revenue growth suggests inability to scale profitably and raises questions about gross margins and operational efficiency
Key Metrics to Watch
- Gross profit margin disclosure and trend toward positive operating margins
- Operating cash flow trajectory and cash burn rate relative to runway
- Revenue per employee or unit economics to assess if growth is profitable-scaled
Financial Metrics
Revenue
33.6M
Net Income
-47.1M
EPS (Diluted)
$-1.05
Free Cash Flow
-31.9M
Total Assets
74.9M
Cash
20.0M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-141.1%
Net Margin
-140.3%
ROE
-141.9%
ROA
-63.0%
FCF Margin
-95.0%
Balance Sheet & Liquidity
Current Ratio
3.31x
Quick Ratio
2.36x
Debt/Equity
0.57x
Debt/Assets
55.6%
Interest Coverage
-2,256.76x
Long-term Debt
18.9M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-10T10:00:22.956997 |
Data as of: 2025-12-31 |
Powered by Claude AI